Evaluation of anti-SARS-CoV-2 antibody in patients with hematological diseases who receive treatment after vaccination.
Not Applicable
Recruiting
- Conditions
- hematological diseases
- Registration Number
- JPRN-UMIN000052145
- Lead Sponsor
- Blood Disorders Center, Aiiku Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are judged to be ineligible for the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of anti-SARS-COV-2 antibody at baseline, 6m, 12m and 18m after treatment for hematological diseases.
- Secondary Outcome Measures
Name Time Method